Mahana Fisher, MD
Family Medicine · Blanding, UTNPI 1700878949
Payments from drug & device makers
Across 132 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$824
- AstraZeneca$212
- Smith+Nephew$92
- Indivior Inc.$90
- E.r. Squibb & Sons, L.L.C.$84
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$77
- plus $592 from 19 others
What the payments were for
- Food & beverage$1,95799%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $824 |
| AstraZeneca | 14 | $212 |
| Smith+Nephew | 6 | $92 |
| Indivior Inc. | 4 | $90 |
| E.r. Squibb & Sons, L.L.C. | 4 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $77 |
| Pfizer | 4 | $69 |
| Braeburn Inc. | 4 | $68 |
| Alkermes, Inc. | 4 | $60 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Novo Nordisk | 3 | $46 |
| Merck | 3 | $36 |
| Lilly USA, LLC | 2 | $28 |
| Misonix Inc | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| Lucid Diagnostics Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Gilead | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
How this compares
$1,972 in reported general payments places this provider in the 70th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 46 | $154,320 |
| EliquisApixaban | 283 | $107,051 |
| RexultiBrexpiprazole | 67 | $75,830 |
| XareltoRivaroxaban | 94 | $46,557 |
| FarxigaDapagliflozin Propanediol | 42 | $45,328 |
| OzempicSemaglutide | 20 | $37,017 |
| JardianceEmpagliflozin | 20 | $17,909 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $15,613 |
| MyrbetriqMirabegron | 54 | $14,441 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,556 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $9,660 |
| LinzessLinaclotide | 26 | $8,276 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $7,739 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $6,352 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $6,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $16 | $154,32046 claims |
| PfizerEliquis | $69 | $107,051283 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $50 | $75,83067 claims |
| Johnson & JohnsonXarelto | $11 | $46,55794 claims |
| AstraZenecaFarxiga | $212 | $45,32842 claims |
| Novo NordiskOzempic | $46 | $37,01720 claims |
| GSKTrelegy Ellipta, Shingrix | $17 | $15,26137 claims |
| AbbVieLinzess | $824 | $8,27626 claims |
| MerckJanuvia | $36 | $4,85315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 928 family medicine providers in Utah.
Other family medicine in Blanding
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
- Katie JulienSouth Jordan$7.1M
- Scott EricksonBountiful$3.7M
- John RichardsSouth Jordan$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.